TITLE

NeXstar Takeout Tastes Medicine of Street Doubt

AUTHOR(S)
Cohen, Judith Radler
PUB. DATE
April 1999
SOURCE
Mergers & Acquisitions Report;04/19/99, Vol. 12 Issue 16, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports that Gilead Sciences Incorporated's takeout of NeXstar Pharmaceuticals Inc. is to close by the end of June 1999. Stock of NeXtar stock; Information on the 0.425 exchange ratio; Various comments on the transaction; Financial performance of both companies in 1998.
ACCESSION #
1785481

 

Related Articles

  • Gilead acquires NeXstar. Dorey, Emma // Nature Biotechnology;Apr99, Vol. 17 Issue 4, p316 

    Reports on the acquisition of NeXstar Pharmaceuticals Inc. by biotechnology company California-based biotechnology company Gilead Sciences Inc. Details of the deal; Purpose of the acquisition; Benefits of the acquisition.

  • Gilead Sciences and Nexstar Agree to a $500 Million Merger.  // Chemical Market Reporter;03/15/99, Vol. 255 Issue 11, p21 

    Reports the merger agreement between Gilead Sciences Inc. and Nexstar Pharmaceuticals Inc. Details on the agreement; Information on both companies.

  • Gilead to buy NeXstar.  // Medical Marketing & Media;Apr99, Vol. 34 Issue 4, p28 

    Reports on the plan of Gilead Sciences Inc. to acquire NeXstar Pharmaceuticals Inc. Terms of the acquisition; Benefits from the acquisition.

  • Gilead Continues to Diversify with $600M Calistoga Deal.  // Bioworld Week;2/28/2011, Vol. 19 Issue 9, p3 

    The article reports on the acquisition of Seattle, Washington-based Calistoga Pharmaceuticals Inc. by Gilead Sciences Inc.

  • Gilead's $11 billion HCV bet. Carey, Karen // Nature Biotechnology;Feb2012, Vol. 30 Issue 2, p122 

    The article reports on the acquisition of New Jersey-based Pharmasset by Gilead Sciences, a developer of human immunodeficiency virus (HIV) drugs.

  • China, Japan Shine in M&A. Yoshida, Kotaro // BioSpectrum;Aug2013, Vol. 11 Issue 8, p55 

    The article reports on the growth of mergers and acquisitions (M & A) of biotechnology and pharmaceutical companies in China and Japan. According to Christoph Bieri, healthcare team chairman of the global M & A advisory firm IMAP Inc., Japan and China showed higher M & A deals in 2012. In...

  • Singular focus spurs deal-making frenzy.  // Medical Marketing & Media;Mar2012, Vol. 47 Issue 3, p38 

    The article reports on Gilead Sciences Inc.'s acquisition of Pharmasset and Bristol-Myers Squibb's and mentions the efforts of pharmaceutical firms in maintaining dominance in therapeutic markets.

  • Gilead to Buy Pharmasset for $11 Bil.  // Chain Drug Review;12/12/2011, Vol. 33 Issue 21, p69 

    The article reports that HIV drug manufacturer Gilead Sciences Inc. is buying Pharmasset Inc., a biotechnological company for 11 billion U.S. dollars.

  • Gilead Buying CGI for up to $120M.  // Bioworld Week;7/5/2010, Vol. 18 Issue 27, p2 

    The article reports on the move of Gilead Sciences Inc. to purchase CGI Pharmaceuticals Inc. with 120-million dollar deal in Foster City, California.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics